An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update

References

• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139.
   PubMed Web of Science ®Google Scholar
• Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2004;350(9):1046–1061.
   Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al., Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2014;4(7):629–640.
   Google Scholar
• Papadimitrakopoulou VA, Mok TS, Han J-Y, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol Off J Eur Soc Med Oncol. 2017;31(11):1536–1544.
   Google Scholar
• Vishwanathan K, Dickinson PA, Bui K, et al. The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers. J Clin Pharmacol. 2018;58(4):474–484.
   PubMed Web of Science ®Google Scholar
• Vishwanathan K, Dickinson PA, So K, et al. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018;84(6):1156–1169.
   PubMed Web of Science ®Google Scholar
• Brown K, Comisar C, Witjes H, et al. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol. 2017;83(6):1216–1226.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al., Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Brown H, Vansteenkiste J, Nakagawa K, et al. Programmed cell death ligand 1 expression in untreated EGFR mutated advanced NSCLC and response to osimertinib versus comparator in FLAURA. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020;15:138–143.
   Google Scholar
• Leighl NB, Karaseva N, Nakagawa K, et al. Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer Oxf Engl. 2020;125:49–57.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al., Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2018;84(1):41–50.
   Google Scholar
• Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38s.
   PubMedGoogle Scholar
• Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med [Internet]. 2020 [cited 2020 Oct 6]; http://www.nejm.org/doi/10.1056/NEJMoa2027071
   Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2020;382(11):863–873.
   Google Scholar
• Zhong W-Z, Wang Q, Mao W-M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–148.
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Ahn M-J, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(26):2702–2709.
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:3290-3297.
   Google Scholar
• Ahn M-J, Kim D-W, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5(11):891–902.
   PubMed Web of Science ®Google Scholar
• Yang JCH, Kim S-W, Kim D-W, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(6):538–547.
   PubMed Web of Science ®Google Scholar
• Park S, Lee M-H, Seong M, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol Off J Eur Soc Med Oncol. 2020. DOI:10.1016/j.annonc.2020.06.017.
   Google Scholar
• Ahn M-J, Chiu C-H, Cheng Y, et al. Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020;15:637–648.
   Google Scholar
• Lee J, Choi YL, Han J, et al. Osimertinib improves overall survival in patients with EGFR-mutated NSCLC with leptomeningeal metastases regardless of T790M mutational status. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020;15(11):1758-1766.
   Google Scholar
• Furuta H, Uemura T, Yoshida T, et al. Efficacy and safety data of osimertinib in elderly patients with NSCLC who harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment. Anticancer Res. 2017;5(9):5231–5237.
   Google Scholar
• Kato Y, Hosomi Y, Watanabe K, et al. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 2018;38(6):2350–2360.
   Google Scholar
• Nakao A, Hiranuma O, Uchino J, et al. Final results from a phase II trial of osimertinib for elderly patients with epidermal growth factor receptor t790m-positive non-small cell lung cancer that progressed during previous treatment. J Clin Med. 2020;9(6):9.
   Web of Science ®Google Scholar
• Planchard D, Brown KH, Kim D-W, et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016;77(4):767–776.
   PubMed Web of Science ®Google Scholar
• Zhao H, Cao J, Chang J, et al. Pharmacokinetics of osimertinib in Chinese patients with advanced NSCLC: a phase 1 study. J Clin Pharmacol. 2016;77(4):504–513.
   Google Scholar
• Cho BC, Chewaskulyong B, Lee KH, et al. Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J Thorac Oncol. 2019;14(1):99–106.
   PubMed Web of Science ®Google Scholar
• Le X, Puri S, Negrao MV, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;14(24):6195–6203.
   Google Scholar
• Mehlman C, Cadranel J, Rousseau-Bussac G, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer Amst Neth. 2019;137:149–156.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:740.
   Google Scholar
• Shah KN, Bhatt R, Rotow J, et al. Abstract 2902: non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC. American Association for Cancer Research; 2019 [cited 2020 Sept 15]. http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2019–2902
   Google Scholar
• Thiagarajan PS, Wu X, Zhang W, et al. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. Oncotarget. 2018;29(50):82013–82027.
   Google Scholar
• Blakely CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49(12):1693–1704.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;49(17):3924–3933.
   Google Scholar
• Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–562.
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(11):2654–2663.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–1534.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8(12):1529–1539.
   PubMed Web of Science ®Google Scholar
• Brown BP, Zhang Y-K, Westover D, et al. On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(11):3341–3351.
   PubMed Web of Science ®Google Scholar
• Oztan A, Fischer S, Schrock AB, et al. Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. Lung Cancer Amst Neth. 2017;111:84–87.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang X-C, Yang -J-J, et al. EGFR L792H and G796R: two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13:1415–1421.
   Google Scholar
• Nukaga S, Yasuda H, Tsuchihara K, et al. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 2017;77(8):2078–2089.
   PubMed Web of Science ®Google Scholar
• Michels S, Heydt C, van Veggel B, et al. Genomic profiling identifies outcome-relevant mechanisms of innate and acquired resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor therapy in lung cancer. JCO Precis Oncol. 2019;3:3.
   Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Wu Y-L, Han J-Y, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2016;7:741.
   Google Scholar
• Ramalingam SS, Yang JC-H, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation–positive advanced non–small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(9):841–849. .
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 Patients with EGFR-mutant lung cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(8):2240–2247.
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7(1):11815.
   PubMed Web of Science ®Google Scholar
• Lee J-K, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(26):3065–3074.
   PubMed Web of Science ®Google Scholar
• Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(4):278–285.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6(1):6377.
   PubMedGoogle Scholar
• Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14:1784–1793.
   Google Scholar
• Weng C-H, Chen L-Y, Lin Y-C, et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 2019;38(4):455–468.
   PubMed Web of Science ®Google Scholar
• Brabletz T, Kalluri R, Nieto MA, et al. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–134.
   PubMed Web of Science ®Google Scholar
• Remon J, Swalduz A, Planchard D, et al. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS One. 2018;18(6):e0234302.
   Google Scholar
• Li N, Guha U, Kim C, et al. Longitudinal monitoring of EGFR and PIK3CA mutations by saliva-based EFIRM in advanced NSCLC patients with local ablative therapy and osimertinib treatment: two case reports. Front Oncol. 2020;15:1240.
   Google Scholar
• Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7:1807–1814.
   Google Scholar
• Jia Y, Yun C-H, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129–132.
   PubMed Web of Science ®Google Scholar
• Haura EB, Cho BC, Lee JS, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(15_suppl):9009.
   Web of Science ®Google Scholar
• Oxnard GR, Yang JC-H, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(4):507–516.
   PubMed Web of Science ®Google Scholar
• Riess JW, Groshen SG, Reckamp KL, et al. Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: an ETCTN California cancer consortium phase I study. J Clin Oncol. 2020;31(15_suppl):9057.
   Google Scholar
• Janne PA, Yu HA, Johnson ML, et al. Safety and preliminary antitumor activity of U3–1402: a HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. J Clin Oncol. 2019;37(15_suppl):9010.
   Web of Science ®Google Scholar
• Uchibori K, Inase N, Araki M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 2017;8(1):14768.
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer Amst Neth. 2017;8:59–61.
   Google Scholar
• Suzawa K, Offin M, Schoenfeld AJ, et al. Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer. JCO Precis Oncol. 2019;3:3.
   Web of Science ®Google Scholar
• York ER, Varella-Garcia M, Bang TJ, et al. Tolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12:e85–e88.
   Google Scholar
• Lu C, Cheng J-T, Kang J, et al. Clinical outcomes of NSCLC patients with acquired RET rearrangement after resistance to osimertinib. J Clin Oncol. 2019;37(15_suppl):e20626–e20626.
   Web of Science ®Google Scholar
• Soria J-C, Wu Y-L, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990–998.
   PubMed Web of Science ®Google Scholar
• Han B, Jin B, Chu T, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial. Int J Cancer. 2017;141(6):1249–1256.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Inoue A, Morita S, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol. 2018;36(15_suppl):9005.
   Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(2):124–136. .
   PubMed Web of Science ®Google Scholar
• Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13:1138–1145.
   Google Scholar
• Ma BBY, Rudin CM, Cervantes A, et al. 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Ann Oncol [Internet]. 2016 [cited 2020 Sept 15]. https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdw594.005
   Google Scholar
• Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112–1115.
   PubMed Web of Science ®Google Scholar